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Abstract
Background: Lycopene, selenium, and vitamin E are three micronutrients commonly consumed and supplemented by men
diagnosed with prostate cancer. However, it is not clear whether consumption of these compounds, alone or in
combination, results in improved outcomes.
Methodology/Principal Findings: We evaluated the effects of dietary lycopene (250 mg/kg diet), selenium (methylsele-
nocysteine, 1 mg/kg diet), and vitamin E (c-tocopherol, 200 mg/kg diet) alone and in combination on the growth of
androgen-dependent Dunning R3327-H rat prostate adenocarcinomas in male, Copenhagen rats. AIN-93G diets containing
these micronutrients were prefed for 4 to 6 weeks prior to tumor implantation by subcutaneous injection. Tumors were
allowed to grow for ,18 weeks. Across diet groups, methylselenocysteine consumption decreased final tumor area
(P=0.003), tumor weight (P=0.003), and the tumor weight/body weight ratio (P=0.003), but lycopene and c-tocopherol
consumption intake did not alter any of these measures. There were no significant interactions among nutrient
combinations on tumor growth. Methylselenocysteine consumption also led to small, but significant decreases in body
weight (P=0.007), food intake (P=0.012), and body weight gain/food intake ratio (P=0.022). However, neither body weight
nor gain/food intake ratio was correlated with tumor weight. Methylselenocysteine, lycopene, and c-tocopherol consumed
alone and in combination did not alter serum testosterone or dihydrotestosterone concentrations; tumor proliferation or
apoptosis rates. In addition, the diets also did not alter tumor or prostate androgen receptor, probasin, selenoprotein 15,
selenoprotein P, or selenium binding protein 2 mRNA expression. However, using castration and finasteride-treated tissues
from a previous study, we found that androgen ablation altered expression of these selenium-associated proteins.
Conclusions: Of the three micronutrients tested, only methylselenocysteine consumption reduced growth of transplantable
Dunning R3327-H prostate tumors, albeit through an unresolved mechanism.
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Introduction
Prostate cancer is the most frequently diagnosed male cancer
in the United States, accounting for about one quarter of all male
cases in 2009 [1]. Selenium, vitamin E, and lycopene, the red-
pigmented carotenoid found primarily in tomatoes, are among
the most commonly used supplements by men diagnosed with
prostate cancer [2,3]. Despite their use by prostate cancer
patients, it has not been established whether supplementation of
these micronutrients, alone or in combination, results in
improved outcomes.
Before embarking on large clinical intervention studies, it is often
best to first exhaust the use of cell culture and animal models. This
has been exemplified by the recent early termination of SELECT, a
large clinical intervention study using selenomethionine and all-rac-
a-tocopherol acetate alone and in combination for prostate cancer
risk reduction, because of the apparent lack of efficacy [4].
Selenomethionine and a-tocopherol have been shown to be only
marginally effective in prostate cancer animal models [5–9].
An additional consideration in developing natural supplements
for cancer prevention or therapy is the selection of the chemical
form of the test compounds. Selenomethionine is less effective than
PLoS ONE | www.plosone.org 1 April 2010 | Volume 5 | Issue 4 | e10423methylselenocysteine at decreasing cancer incidence and/or
progression in breast [10,11], colon [10,12], and prostate cancer
models [5,7,8,13]. For vitamin E, epidemiological [14–17], in vitro
[18–20], and animal studies [5,6,21–24] are more supportive of c-
tocopherol than a-tocopherol for decreasing prostate cancer risk,
cell proliferation, or tumor development or growth. Likewise, we
reported that lycopene alone is not as effective as 10% tomato
powder at decreasing the development or progression of prostate
cancer in two animal models [25,26]. Although these compounds
have not been particularly effective when supplemented alone,
compelling evidence supports their use in combination [21,27–31].
On the basis of this notion of combinatorial approaches to
reduce tumor growth, we tested the ability of lycopene,
methylselenocysteine, and c-tocopherol alone and in combination
to decrease the growth of androgen-dependent Dunning R-3327H
rat prostate adenocarcinomas. The Dunning R-3327H model is a
transplantable tumor model that originated from a spontaneous
tumor in a Copenhagen rat [32]. It is an appropriate model for
this study because it is a slow-growing, nonmetastatic, androgen-
responsive [32,33] tumor that responds to dietary interventions
[26,34]. We hypothesized that combinations of these micronutri-
ents would additively or synergistically decrease tumor area and
weight.
Results
The following abbreviations are used to represent the diet
groups: lycopene, Lyc; selenium, Se; Vitamin E, VE; Lyc + Se; Lyc
+ VE; Lyc + Se + VE. Tumor incidence was greater than 99%,
with only one rat injection site not developing a tumor (Lyc + Se).
This site was not included in the tumor area or tumor weight
calculations. Selenium consumption led to a significant decrease in
final tumor area (P=0.003, Figure 1) and tumor weight (P=0.003,
Table 1). Neither lycopene nor vitamin E consumption altered
final tumor area or tumor weight, and no nutrient combination
interactions significantly influenced tumor growth.
Diets were well accepted and consumed; nevertheless, selenium
consumption led to a significant decrease in final body weight
(P=0.007, Table 1). Food intake varied by less than 1 g/day
between diet groups (Table 1), but selenium consumption was
associated with a small, yet significant, decrease in daily food
intake (P=0.012) and gain/food intake ratio ([body weight
gained/total food intake] 61000, P=0.022, Table 1). To
normalize tumor weight for body weight, we calculated the tumor
weight/body weight ratio. This measure had the same P-value
(P=0.003) as the P-value for tumor weight alone. The correlations
between body weight and tumor weight (r=0.12) and gain/food
intake ratio and tumor weight (r=0.09) were not significant.
We used high performance liquid chromatography (HPLC) to
measure hepatic lycopene, a-tocopherol, and c-tocopherol con-
centrations and neutron activation analysis to quantify selenium
concentrations to verify that supplementation was effective and
whether nutrient accumulation interactions had occurred. All diets
contained 66 mg/kg diet a-tocopherol, c-tocopherol-supplement-
ed diets contained 195 mg/kg diet c-tocopherol, and lycopene-
supplemented diets contained 291 mg/kg diet lycopene. Hepatic
lycopene concentrations in the Lyc + VE group were increased
compared with Lyc alone (Table 2, P,0.05). There was no
difference in hepatic c-tocopherol concentrations between vitamin
E-supplemented groups or in a-tocopherol among all dietary
groups. Lycopene and c-tocopherol were not detected in
nonsupplemented groups (Table 2). Neutron activation analysis
showed that selenium-supplemented diets contained 1.03 mg/kg
diet, whereas nonsupplemented diets contained 0.09 mg/kg diet
selenium. Selenium supplementation increased hepatic selenium
concentrations (Table 2, P,0.05), but there were no differences
between selenium-supplemented groups.
Because of the importance of androgens in stimulating the
growth of Dunning R3327-H tumors, we evaluated whether
selenium consumption altered serum testosterone or dihydrotes-
tosterone concentrations. There were no differences in either
serum androgen among dietary groups (Table 3). Other potential
mechanisms for decreased tumor growth with selenium consump-
tion include altered tumor proliferation and/or apoptotic rates.
We used immunohistochemistry to calculate a tumor proliferation
index and count tumor apoptotic cells; however, there were no
significant differences in these measures among dietary groups
(Table 3). We next measured the activity of the selenoenzyme,
glutathione peroxidase, to determine whether selenium consump-
tion induced this enzyme in the prostate and/or tumor. We found
no difference in glutathione peroxidase activity in the prostate or
tumor with selenium consumption compared with animals fed the
control diet (data not shown).
Selenium treatment, or consumption, has been reported to alter
androgen receptor signaling or expression [35–45]. Thus, we
measured androgen receptor and probasin mRNA expression in
the normal prostate and tumor of all dietary groups. Probasin
(prostate basic protein) is a prostate-specific, androgen-response
gene [46]. There was no difference in androgen receptor or
probasin mRNA expression between diet groups in either tissue
(data not shown).
We next examined whether selenium consumption altered the
mRNA expression of three selenium-associated proteins: SepP,
Sep15, and SBP2. We selected these selenium-associated proteins
for two reasons. First, their expression has been reported to
decrease in prostate cancer tissue and/or cell lines compared with
normal tissue or less-advanced prostate cancer cell lines [47–49].
In addition, their expression is altered by androgens [47,50–54].
Nonetheless, there was no difference in SepP, Sep15, and SBP2
mRNA expression between diet groups in either the prostate or
the tumor (data not shown).
Because we did not find differences in SepP, Sep15, and SBP2
mRNA expression with selenium consumption, we measured
mRNA expression in prostates and tumors from finasteride-treated
and castrated rats from a previous study [26]. This was done to
ensure that the expression of SepP, Sep15, and SBP2 was altered
by androgens as reported previously [47,50,52–54]. Finasteride is
Figure 1. Dunning R3327-H tumor area (n=26 to 38). Selenium
consumption led to a significant decrease in tumor area (P=0.003), but
vitamin E and lycopene consumption did not alter tumor areas.
doi:10.1371/journal.pone.0010423.g001
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one to dihydrotestosterone, making it a weak androgen ablation
therapy. In the prostate, castration decreased prostate Sep15 levels
(P=0.0003, Table 4), whereas finasteride treatment decreased
prostate SepP expression (P=0.008, Table 4). In the prostate,
SBP2 expression was increased by both finasteride treatment
(P=0.002, Table 4) and castration (P=0.008, Table 4). In the
tumor, castration decreased Sep15 expression levels (P=0.003,
Table 4), and there were no alterations in SBP or SepP expression
levels or effects of finasteride treatment.
Discussion
The major finding of this study was that dietary methylseleno-
cysteine, but not lycopene or c-tocopherol, reduced prostate
Dunning R3327-H adenocarcinoma growth in male Copenhagen
rats. Contrary to our hypothesis and others’ findings [21,27–31], we
did not observe additive or synergistic reductions in tumor growth
with combinations of the different micronutrients. The ineffective-
ness of lycopene alone is, in general, consistent with our [25,26] and
others’ findings [21,22,55] in rodent prostate cancer models. Unlike
the inhibition seen previously in transgenic prostate cancer models
[23,24], c-tocopherol did not inhibit tumor growth in the present
study. These differences may indicate that c-tocopherol prevents
developmentofprostate cancer,whichcannotbe investigatedinthis
model, rather than inhibits growth of prostate tumors.
The dietary level of lycopene is the same as our previous rat prostate
cancer studies [25,26], and was originally selected to yield lycopene
tissue levels similar to what occurs in humans [56,57]. We originally set
o u tt os u p p l e m e n tt h ed i e t sw i t h2m gS e / k gd i e tb e c a u s ei nb r e a s t
cancer models this level was able to decrease cancer incidence by 50%
and did not result in adverse outcomes, such as decreased food intake
or body weights [10]. However, the diet analysis revealed that the diet
contained 1 mg Se/kg diet. For c-tocopherol, we chose 200 mg c-
tocopherol/kg diet based on the finding that 150 mg c-tocopherol/kg
diet increased both a-tocopherol and c-tocopherol tissue levels in
vitamin E deficient rats [58].
The small but significant decreases in body weight, food intake,
and gain/food intake ratio with methylselenocysteine consumption
was unexpected. Of 20 publications identified [8,12,13,59–75], only
Table 1. Final body weight, food intake, gain/food intake ratio, tumor weight, and tumor weight/final body weight ratio
1.
Group Final Body Weight (g) Food Intake (g/d)
Gain/Food intake Ratio
(g gained/g total food
intake) 61000 Tumor Weight (g)
Tumor Weight/Final Body
Weight Ratio 610000
Control 36067 (19) 16.760.3 (19) 70.762.2 (19) 1.2660.16 (38) 34.064.3 (38)
VE
2 36569 (14) 16.660.4 (15) 70.862.3 (14) 1.4360.19 (27) 38.465.2 (27)
Lyc + VE 36465 (14) 16.660.4 (14) 72.162.3 (14) 1.5260.26 (28) 40.066.8 (28)
Lyc 364611 (14) 16.760.3 (14) 72.463.6 (14) 1.1360.16 (30) 31.264.6 (30)
Lyc + Se 34368 (14) 16.260.2 (14) 68.862.9 (14) 0.9660.14 (27) 26.863.9 (27)
Se + VE 359610 (14) 16.660.3 (14) 68.962.4 (14) 1.2160.20 (27) 32.865.3 (27)
Lyc + Se + VE 33867 (14) 16.060.3 (15) 64.661.8 (15) 0.8060.10 (29) 22.462.7 (29)
Se 34769 (14) 16.160.4 (14) 6762.7 (14) 0.8060.11 (26) 21.963.1 (26)
1Data are means 6 SEM, ( ) sample size, selenium consumption resulted in a significant decrease in final body weight (P=0.007), food intake (P=0.012), gain/food intake
ratio (P=0.022), tumor weight (P=0.003), and tumor weight/body weight ratio (P=0.003).
2Lyc, lycopene; Se, selenium; VE, vitamin E.
doi:10.1371/journal.pone.0010423.t001
Table 2. Hepatic lycopene, c-tocopherol, a-tocopherol, and selenium levels
1.
Group Total
2 Lycopene (mg/g) c-tocopherol
3 (mg/g) a-tocopherol (mg/g) Selenium (mg/g)
Control ND
4 ND 7664 0.8360.03
VE
5 ND 5.560.6 7064 0.8560.02
Lyc + VE 203613
* 6.161.1 7767 0.7960.06
Lyc 148620 ND 7263 0.7760.06
Lyc + Se 17169N D 7 8 67 1.1560.06
**
Se + VE ND 6.462.0 6465 1.1660.02
**
Lyc + Se + VE 149613 3.960.7 7263 1.1260.04
**
Se ND ND 6765 1.1760.03
**
1Data are means 6 SEM (n=6),
*P,0.05 vs. Lyc group,
**P,0.05 vs. control group.
2All-trans + cis isomers.
3Limit of detection 0.6 mg/g.
4Not detectable.
5Lyc, lycopene; Se, selenium; VE, vitamin E.
doi:10.1371/journal.pone.0010423.t002
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vegetable powder that accumulates this compound, for $10 weeks,
reported a significant decrease in body weight. However, the
significance of selenium consumption’s reduction in tumor weight
was not altered when we controlled for body weight by calculating
the tumor/body weight ratio. Further support is provided by
correlations between final body weight and tumor weight or gain/
food intake ratio and tumor weight that were not statistically
significant. Overall, we cannot rule out that decreased body weight,
food intake, gain/food intake ratio, or cytoxic effects of selenium
may have played a small role in the decrease in tumor growth.
For lycopene, selenium, and vitamin E status, we measured
hepatic concentrations, which are a good indicator of prostate and
tumor lycopene [26] and selenium concentrations [8] as well as
overall body status. Selenium consumption resulted in a 42%
increase in hepatic selenium concentrations, similar to what has
been reported previously [8]. There was no increase in hepatic a-
tocopherol concentrations with c-tocopherol supplementation as
reported previously [58]. Similar to our results, a recent
publication also found no alteration in plasma a-tocopherol
concentrations in transgenic male rats fed c-tocopherol [24]. We
found a significant 37% increase in hepatic lycopene concentra-
tions with c-tocopherol consumption that we believe may be due
to the antioxidant action of c-tocopherol, which could prevent
oxidation of lycopene. However, hepatic lycopene concentrations
were not increased in the Lyc + Se + VE group compared with the
Lyc group. More research on combinations of these nutrients is
needed to characterize these interactions.
Despite the reduction in tumor weight and final tumor area with
selenium consumption, tumor proliferation or apoptosis rates were
unaltered. The slopes of the increase in tumor area from week 17 to
week 18 (Figure 1) were similar among all diet groups, indicating
similar growthrates attheendof the study.Thus, itis possiblethat if
we had terminated the study earlier, when growth rates were
different, we may have found differences in tumor proliferation and
apoptosisrates.Seleniumconsumptionalsodidnotalterglutathione
peroxidase activity in the prostate or tumor, similar to previous
findings in the liver and colon of mice [76]. To the best of our
knowledge, we are the first to determine that selenium consumption
does not alter glutathione peroxidase activity in the prostate or
prostate tumors.Selenium consumption did not alter androgen
receptor, probasin, SBP2, Sep15, or SepP prostate or tumor mRNA
expression. Our finding of no alteration of androgen receptor
expression with methylselenocysteine consumption differs from
consumption and intraperitoneal injection of methylselenocysteine
that decreased androgen receptor expression in the rat prostate [45]
and LNCaP tumor xenographs in nude mice [44], respectively. The
reason for the differencein results is not clear butcould be relatedto
our lower selenium dose, animal model, and/or method of gene
expression measurement. To the best of our knowledge, we are the
first to determine whether selenium consumption alters expression
of SBP2, Sep15, and SepP in the prostate or prostate tumors. There
are two very similar SBPs in mice, SBP1 and SBP2 [77], but in both
rats and humans, only one SBP has been identified. The human
gene is SBP1 [78], and the rat gene is SBP2 [79]. Our finding of no
differences in SBP2 with selenium is in agreement with the lack of
Table 3. Serum testosterone, dihydrotestosterone levels, tumor proliferation index, and apoptotic cell numbers
1.
Diet Group
Serum Testosterone
(ng/mL)
Serum Dihydrotestosterone
(pg/mL)
Tumor Proliferation
Index (%)
Tumor Apoptotic
Cell Number
Control 1.460.2 (17) 8869 (14) 45.264.7 (10) 8.260.9 (20)
VE
2 1.260.1 (13) 8168 (13) 44.264.8 (10) 9.361.1 (20)
Lyc + VE 1.160.1 (14) 8368 (14) 44.963.1 (10) 7.560.9 (20)
Lyc 1.260.1 (11) 81610 (12) 43.765.5 (10) 9.660.9 (20)
Lyc + Se 1.460.1 (10) 8666 (12) 50.164.5 (10) 7.960.6 (20)
Se + VE 1.1 60.1 (14) 8068 (14) 47.665.0 (10) 10.461.0 (20)
Lyc + Se + VE 1.360.1 (13) 8167 (15) 54.263.7 (10) 7.360.7 (20)
Se 1.160.1 (12) 7568 (13) 46.764.4 (10) 7.660.6 (20)
1Data are means 6 SEM, ( ) sample size, no significant differences for any of these parameters.
2Lyc, lycopene; Se, selenium; VE, vitamin E.
doi:10.1371/journal.pone.0010423.t003
Table 4. Prostate and tumor selenoprotein 15 (Sep15), selenoprotein P (SepP), and selenium binding protein 2 (SBP2) mRNA
expression in castrated and finasteride treated rats
1.
Prostate Tumor
Group Sep15 (n=5–6) SepP (n=5–6) SBP2 (n=5–6) Sep15 (n=11–13) SepP (n=11–13) SBP2 (n=10–13)
Control (Cas) 1.060.1 1.060.2 1.060.1 1.060.1 1.060.1 1.060.1
Castrated 0.460.1
** 0.960.1 2.060.1
** 0.760.1
** 1.160.1 1.160.1
Control (Fin) 1.060.2 1.060.1 1.060.1 1.060.1 1.060.1 1.060.1
Finasteride 0.860.1 0.660.1
* 1.860.2
* 1.060.1 1.260.1 0.860.1
1Values are means 6 SEM, asterisks indicate significant differences compared with the corresponding control,
*P,0.05,
**P,0.01.
doi:10.1371/journal.pone.0010423.t004
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levels [80]. However, it differs from the increased SBP1 expression
with methylselenocysteine treatment of normal human ovarian
surface cells in vitro and decreased expression in three of the four
human ovarian cancer cell lines [51]. Our finding that Sep15
expression was not altered by selenium consumption or deficiency is
consistent with previous studies in which mouse hepatic Sep15
protein [76,81] and mRNA levels [81,82] were not altered with
selenium consumption or deficiency. We did not find an alteration
in SepP in either tissue, and hepatic SepP expression levels
previously were reported to be decreased in selenium-deficient rats
[83], but not in the colon of selenium-deficient mice[82].
In castrated or finasteride-treated rats, prostate SBP2 mRNA
expression was increased. This is in agreement with work
investigating the effects of dihydrotestorone treatments of prostate
cancer cells in culture [47,50]. In contrast, neither castration nor
finasteride treatment altered tumor SBP2 expression. Castration
significantly decreased prostate and tumor Sep15 expression similar
to the decrease in rat ventral prostate Sep15 expression following
castration reported previously [52]. It should be noted that this was
the only gene altered by castration in both the prostate and tumor.
Finasteride treatment decreased prostateSepP expression. Previously,
castration was reported to decrease kidney but not hepatic SepP
expression in mice [53]. In addition, in LNCaP cells, in vitro synthetic
androgen R1881treatment increased SepP expression [54]. Thus, it
appears that SepP expression is stimulated by androgens. Overall,
Dunning tumor gene expression seemed to be less responsive to
androgen ablation than prostate gene expression. This may be due to
the location of the tumor or its altered physiology.
In conclusion, only methylselenocysteine consumption decreased
tumor weight and final tumor area, and there was no additional
benefit of consuming lycopene and/or c-tocopherol. Methylsele-
nocysteine consumption did not alter serum androgens; tumor
proliferation rates; tumor apoptosis rates; glutathione peroxidase
activity; or androgen receptor, probasin, Sep15, SepP, or SBP2
expression. Thus, another mechanism of action for selenium’s
ability to decrease tumor growth is yet to be elucidated. Castration
decreased prostate and tumor Sep15 expression and increased
prostate SBP2 expression. Finasteride treatment decreased prostate
SepP expression and increased prostate SBP2 expression.
The SELECT results show the importance of conducting
preclinical animal models and publishing those results even if
nonsignificant effects are seen [84,85]. Evidence in preclinical
models suggests that all forms of selenium (selenomethionine,
selenite, etc.) should not be lumped together because of their
varied efficacy. Instead, studies should be interpreted according to
what selenium compound was administered with the current study
adds to the methylselenocysteine and prostate cancer literature
[86]. Our lycopene and/or c-tocopherol results add to growing
evidence suggesting that isolated nutrients, alone or in combina-
tion, may not be an effective strategy for decreasing tumor growth
[85,87,88].
Materials and Methods
Ethics Statement
The University of Illinois Laboratory Animal Care Advisory
Committee approved all animal procedures.
Experimental Diets
Study rats were fed the control diet for 1 week after receipt and
then were randomized into one of eight AIN-93G [89] based
powder study diet groups (Table 5) for 4 to 6 weeks prior to tumor
implantation. Diets were balanced for protein, fat, energy, and
fiber and stored at 4uC in the dark. All diets were provided ad
libitum. Diets were replaced and food intakes calculated every 48 h.
Fresh diets were prepared monthly (all diet ingredients from
Harlan Teklad, Madison, WI, unless otherwise noted).
Tocopherol-stripped soybean oil (Dyets, Inc., Bethlehem, PA)
was used to limit exogenous, nonsupplemented tocopherol levels.
Table 5. AIN-93G-based lycopene, selenium, and vitamin E diet formulations.
Diets Composition (g) Control Lyc
1 Se VE Lyc + Se Lyc + VE Se + VE Lyc + Se + VE
Cornstarch 395 395 385 395 385 395 385 385
Casein 200 200 200 200 200 200 200 200
Maltodextrin 132 132 132 132 132 132 132 132
Sucrose 100 100 100 100 100 100 100 100
Soybean Oil
2 70 70 70 70 70 70 70 70
Cellulose 50 50 50 50 50 50 50 50
Mineral Mix 35 35 35 35 35 35 35 35
Vitamin Mix
3 10 10 10 10 10 10 10 10
L-Cystine 3 3 3 3 3 3 3 3
Choline Bitartrate 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5
Lyc Beadlets
4 - 2.5 - - 2.5 2.5 - 2.5
Placebo Beadlets 2.5 - 2.5 2.5 - - 2.5 -
c-Tocopherol - - - 0.2 - 0.2 0.2 0.2
Se Premix
5 - - 10 - 10 - 10 10
Total 1000 1000 1000 1000 1000 1000 1000 1000
1Lyc, lycopene; Se, selenium; VE, vitamin E.
2Tocopherol-stripped.
327 mg/kg diet as all-rac-a-tocopherol acetate.
410% lycopene.
5200 mg/kg of selenium in cornstarch as methylselenocysteine.
doi:10.1371/journal.pone.0010423.t005
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formulated to provide the National Research Council requirement
for rats (27 mg/kg diet as all-rac-a-tocopherol acetate) [90] instead
of the 75 mg/kg diet normally provided by AIN93-G diets [89].
Vitamin E was supplemented as c-tocopherol (D-Gamma
Tocopherol 90, Eisai Food & Chemical Co., Ltd., Tokyo, Japan)
at 200 mg/kg diet in VE groups. Lycopene was added to diets in
the form of 10% lycopene beadlets (redivivo
TM, DSM, Basel,
Switzerland) to deliver 250 mg/kg diet as we have done previously
[25,26]. Equivalent amounts of placebo beadlets (DSM) were
used in diets not containing lycopene. Selenium was supplemented
in the form of methylselenocysteine (Se-Methylseleno-L-
cysteine, PharmaSe, Lubbock, TX) at 1 mg/kg diet of elemental
selenium.
Rats
One hundred and twenty-six <100 gram male Copenhagen
rats (Cop 2331; Harlan, Indianapolis, IN) were individually
housed in wire-bottomed cages. Rats were monitored daily and
weighed twice weekly. Two control rats were euthanized prior
to study completion because of high tumor burden. Five other
rats were euthanized prior to study completion for health
reasons unrelated to tumor growth (1 Se, 1 VE, 1 Lyc + Se, 1
Lyc + VE, 1 VE + Se); 119 rats completed the study. The study
was carried out in three cohorts (n=6 or 7) with 6 or 7 control
rats per cohort. Cohorts were necessary because the rats could
not be purchased at one time. Coh o r tw a su s e da sac o v a r i a t ei n
statistical analysis to control for possible differences between
cohorts.
Dunning R3327-H Tumor Implantations
Ten <150 g male Copenhagen donor rats (Harlan, Indianapolis,
IN) had tumor pieces coated in Matrigel
TM Basement Membrane
Matrix (BD Biosciences, Bedford, MA)subcutaneously implantedin
their hind flanks. Tumors were allowed to grow for 15 to 20 weeks
and then were harvested for implantation into study rats.
Tumors were sterilely harvested from donor rats by removing
the tumor capsule, necrotic areas, and large blood vessels. The
remaining tissue was mixed with Hanks Balanced Salt Solution,
minced, pushed through a 20 mesh sieve, and placed in a
50 mL centrifuge tube. The solution was centrifuged at 2006g
for 10 minutes, and the supernatant was removed. The
remaining tumor pellet was mixed with Matrigel
TM at a
concentration of 100 mg tumor/mL, and 0.2 mL (<20 mg of
tumor) was injected with 19-gauge needles into both rear flanks
of study rats. Tumors were allowed to grow for <18 weeks until
study termination. Tumors were palpated weekly, and tumor
length and width were measured with calipers. From these
measurements, tumor area was calculated using the formula for
area of an ellipse: area=p*(length/2)*(width/2). When a tumor
was not found, a zero was recorded for that week. At study
termination, rats were anesthetized with CO2, blood was taken
via cardiac puncture, tumors were removed and cleaned, and
tumor weights were recorded. Tumor and selected tissues were
f l a s hf r o z e ni nl i q u i dn i t r o g e na n dt h e ns t o r e di na280uC
freezer. In addition, a piece of tumor was placed in 10%
formalin (Sigma-Aldrich) for 24 to 48 hours before being
moved to 70% ethanol.
Hepatic and Diet Lycopene and Vitamin E Quantification
For liver, 0.1 g of tissue was placed into a 50-mL glass centrifuge
tube. Ethanol containing 0.1% butylated hydroxytoluene (3.5 mL)
was added along with deionized distilled water (1.5 mL) and
ascorbic acid (0.25 g). Tocol (Matreya, Pleasant Gap, PA) and b-
carotene (Sigma-Aldrich, St. Louis, MO) were added as internal
standards for tocopherols and carotenoids, respectively. Saturated
potassium hydroxide (1 mL) was then added, and samples were
vortexed and saponified at 60uC for 30 min in a water bath.
Ascorbic acid was necessary to prevent oxidation of vitamin E
during saponification as described previously [91]. Test tubes were
then removed from the water bath and placed on ice, and
deionized distilled water (2 mL) was added prior to extraction
three times with hexane (6 mL). The extracts were dried down in a
Speedvac concentrator (model AES1010; Savant, Farmingdale,
NY), covered with argon, and stored at 220uC for less than
48 hours before HPLC analysis. The procedure was the same for
diet extraction except 0.25 g of diet was extracted, and internal
standards were not used. Samples were analyzed by using an
isocratic HPLC method described previously with minor modifi-
cations [92]. The mobile phase consisted of acetonitrile/dioxane/
2-propanol/methanol/triethylamine (800/150/25/25/1) with
200 mM ammonium acetate in the alcohol component. Samples
were reconstituted in ethyl acetate: mobile phase (100:35). The
HPLC system consisted of a Varian Prostar 325 UV-Vis Dual
Wavelength Detector (Walnut Creek, CA) monitoring 300 nm
and 450 nm wavelengths, a Varian 410 Autosampler, Rainin SD-
200 Dynamax pumps, a precolumn (Upchurch Scientific, Oak
Harbor, WA) packed with ODS C-18 (Alltech Associates,
Deerfield, IL), a C-18 Waters Spherisorb 3 mM ODS2
4.66150 mm column (Milford, MA), and a CERA 250 column
cooler (Baldwin Park, CA) set at 16uC for the 25-minute run
duration. Our laboratory routinely participates in the National
Institutes of Standards in Technology micronutrient proficiency
testing program, and our values for lycopene, a-tocopherol, and c-
tocopherol normally are within one standard deviation of the
median.
Selenium and Serum Androgen Quantification
Hepatic and diet selenium concentrations were determined by
neutron activation analysis [93] at the University of Missouri
Research Reactor Center (reported as wet weight concentrations).
Serum testosterone and dihydrotestosterone concentrations were
determined with DSL-4000 and DSL-9600 radioimmunoassay
kits, respectively (Diagnostic Systems Laboratories Inc., Webster,
TX) according to the manufacturer’s instructions.
Tumor Histology and Immunohistochemistry
At study termination, a piece of Dunning R3327-H tumor
was fixed in 10% formalin (Sigma-Aldrich) for 24 to 48 hours
before being moved to 70% ethanol. Samples were then
processed overnight in a vacuum infiltration processor E300,
(Sakura Finetek, Torrance, CA), paraffin embedded by using a
Tissue Tek TEC Embedding Center (Sakura Finetek), sectioned
at 3 mM by using a HM315 Microm Microtome, and
transferred to positively charged barrier slides (BioGenex, San
Ramon, CA). Slides were deparafinized and hydrated by using a
Sakura DRS 2000 followed by methanol 3% H2O2 solution for
15 min. To unmask proliferating cell nuclear antigen (PCNA),
slides were placed in citrate buffer (pH 6) in a decloaking
chamber for 30 seconds at 125uCa n d1 0s e c o n d sa t9 0 uC. The
slides were then transferred to a Biogenex i6000 immunostainer,
where the slides were blocked for 10 minutes with Power
Block
TM (BioGenex) then blocked with avidin and biotin for 15
minutes each. Rabbit anti-PCNA antibody (Dako, Carpinteria,
CA) was incubated for 30 minutes followed by the DakoCyto-
mation LSAB2 System. The LSAB2 Biotinylated Link was
incubated for 15 min, the LSAB2 Streptavidin-HRP label for 15
minutes, followed by 3,39-diaminobenzidine tetrahydrochloride
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with Mayer’s hematoxylin (BioGenex) for 1 minute. The PCNA
images were blindly captured and quantified as described
previously [26]. Two representative images per tumor were
captured, and a proliferative index percentage, (PCNA positive/
total nuclei counter) 6100, was calculated. The proliferative
index reported is the mean of two proliferative index
percentages per tumor.
Apoptosis was measured with an ApoptagH Peroxidase In Situ
Apoptosis Detection Kit S7100 (Chemicon International, Teme-
cula, CA) according to the manufacturer’s instructions except that
slides were counterstained with Mayer’s hematoxylin rather than
methyl green. Images were blindly captured and quantified as
described previously [26]. Two representative images, without
artifacts, from each tumor were quantified by counting the
number of nuclei at 4006 magnification. The apoptotic cell
number reported is the mean of the two apoptotic nuclei values
per tumor.
Real-Time PCR
Castration and finasteride tissues were from two separate studies
described previously [26]; therefore, controls were needed as a
comparison to both groups. Tumors and dorsolateral plus anterior
prostate lobes were extracted with the PureLink Micro-to-Midi
Total RNA Purification System (Invitrogen, Carlsbad, CA)
according to the manufacturer’s instructions. Tumors and dorso-
lateral prostates from the Lyc, Se, and VE groups were extracted
using TrizolH reagent (Invitrogen, Carlsbad, CA) according to the
manufacturer’s instructions. After extraction, the sample was
treated with DNase (DNase I, New England Biolabs, Ipswich,
MA) following the manufacturer’s typical reaction instructions
except 20 mg of RNA and four units of DNAse I were used. The
RNA was then ethanol precipitated [94] and resuspended in
RNase-free water. The RNA was run on an agarose gel to examine
RNA integrity, and samples of sufficient quality were used to
synthesize cDNA withHigh-CapacitycDNA Reverse Transcription
Kits (Applied Biosystems, Foster City, CA) and an Eppendorf
Mastercycler Gradient (Westbury, NY).
Primers were selected across exon boundaries by using Primer
Express software. Primers (MWG, Huntsville, AL) were validated to
ensure efficiency and amplification of a single amplicon. The primers
selected were: androgen receptor forward AGAACTACTCCG-
GACCTTATGGG, reverse TGGTCCCTGGTACTGTCCAAAC;
probasin forward AGAAATGACGTTACACGAGTGGC, reverse
CAGTTGCCTGCCTTTCGC; SepP forward AGCCAGCTGA-
TACCTGTGCC, reverse CGCAGGTCTTCCAATCTGGA;
Sep15 forward AACCCAAACTGTTCAGAGGTCTACA, reverse
GGTCTGAGCCTCGAACATACTTG; and SBP2 forward
GCCTCACTGGGCAGATCTTC, reverse CAGAGCCTCCTT-
TAACAATGCTG.
The rRNA L7a was used as an internal control by using previously
published sequences [95]. We verified equivalent expression between
diet and treatment groups in both tissues examined. Real-time PCR
was performed with SYBR Green Mastermix (Applied Biosystems), a
7900 Fast HT Real-Time PCR machine (Applied Biosystems), and
4 ng prostate or tumor cDNA template according to the manufac-
turer’s instructions. The relative mRNA abundance was determined
by using the comparative critical threshold method and is expressed
relative to the control diet group [96].
Gluathione Peroxidase Activity
Frozen dorsolateral prostate and tumor samples were
resuspended in cold sodium phosphate buffer (0.1M, pH 7.0)
and lysed by sonication. Total glutathione peroxidase activity
was determined using a standard coupled spectrophometric
method based on the consumption of reduced NADPH
measured spectrophotometrically by absorbance at 339 nm in
a reaction containing reduced glutathione, glutathione reduc-
tase, tissue lysates, and hydrogen peroxide as described
elsewhere [97].
Statistics
Tumor weight; final tumor area; final body weight; daily food
intake; gain/food intake ratio; tumor weigh/body weight ratio;
proliferation indexes; apoptotic cell numbers; and Lyc, Se, and
VE tumor and prostate gene expression were analyzed by using
dummy-coded multiple linear regression to look for the effects of
lycopene, selenium, and vitamin E consumption and interac-
tions among these nutrients [98,99]. Cohort was used as a
covariate (effects coded) but was retained only in the models for
final tumor area, daily food intake, and gain/food intake ratio.
Hierarchical analysis revealed that covariate interaction terms
and treatment interaction terms did not account for a significant
amount of variance; thus, these terms were removed from all the
models. For tumor weight; final body weight; tumor weight/
body weight ratio; proliferation indexes; apoptotic cell numbers;
and Lyc, Se, and VE gene expression, the final models
contained only the three main treatment variables (Lyc, Se,
and VE). The natural logs of both tumor area and tumor weight
were used to correct violations of model assumptions. Tumor
weight analysis with proc univariate in SAS identified five very
large, outlying tumors (greater than 1.56 interquartile range).
T h e s ef i v et u m o r s( 2S e ,1V E ,1S e+ VE, 1 Lyc + Se + VE)
were excluded from tumor weight and final tumor area analysis.
One rat (Lyc) was excluded from gain/food intake ratio analysis
because of weight loss at the end of the study. Serum
testosterone, serum dihydrotestosterone, hepatic lycopene,
hepatic vitamin E, and hepatic selenium concentrations were
analyzed using ANOVA with Dunnett’s test. Correlations of
final body weight with tumor weight and final body weight with
gain/food intake ratio were performed using the proc corr
command in SAS. Castration and finasteride treatment
expression levels were analyzed using two-sample t-tests.
Natural logs of a number of castration and finasteride treatment
gene expression levels were used to correct for assumption
violations. When this transformation did not correct assumption
violations, the Wilcoxon Rank Exact Sum test [100] was used.
All statistics were performed using SAS 9.1 (Carey, NC), and
P,0.05 was considered significant.
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